DrugPatentWatch Database Preview

Tris Pharma Inc Company Profile

« Back to Dashboard

What is the competitive landscape for TRIS PHARMA INC, and what generic alternatives to TRIS PHARMA INC drugs are available?

TRIS PHARMA INC has twenty-five approved drugs.

There are six US patents protecting TRIS PHARMA INC drugs.

There are nineteen patent family members on TRIS PHARMA INC drugs in fourteen countries and nineteen supplementary protection certificates in eight countries.

Summary for Tris Pharma Inc

International Patents:	19
US Patents:	6
Tradenames:	24
Ingredients:	23
NDAs:	25
Drug Master File Entries:	5
Patent Litigation for Tris Pharma Inc:	See patent lawsuits for Tris Pharma Inc

Drugs and US Patents for Tris Pharma Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tris Pharma Inc	PROMETHAZINE HYDROCHLORIDE	promethazine hydrochloride	SYRUP;ORAL	091675-001	Jun 28, 2012	AA	RX	No	No
Tris Pharma Inc	IBUPROFEN	ibuprofen	SUSPENSION/DROPS;ORAL	079058-001	Aug 31, 2009		OTC	No	No
Tris Pharma Inc	DEXTROAMPHETAMINE SULFATE	dextroamphetamine sulfate	SOLUTION;ORAL	203644-001	May 29, 2013	AA	RX	No	No
Tris Pharma Inc	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	202214-001	Mar 27, 2013	AA	RX	No	No

Non-Orange Book US Patents for Tris Pharma Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,675,704	Modified release formulations containing drug-ion exchange resin complexes
8,491,935	Modified release formulations containing drug-ion exchange resin complexes
8,202,537	Modified release formulations containing drug-ion exchange resin complexes
9,549,989	Modified release formulations containing drug-ion exchange resin complexes

International Patents for Tris Pharma Inc Drugs

Country	Document Number	Estimated Expiration
Taiwan	200812649
Austria	536867
Brazil	PI0709606
Russian Federation	2435569

Supplementary Protection Certificates for Tris Pharma Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0008	Belgium		PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
323	Luxembourg		PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
2013 00059	Denmark		PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
00C/032	Belgium		PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Tris Pharma Inc